Potential usefulness of bovine lactoferrin for adjunctive immunotherapy for mucosal Candida infections

Immunosuppressed children and adults have a higher prevalence of oropharyngeal candidiasis. In this patient population, anti-fungal therapy of this condition is often ineffective, and new approaches to treatment are needed. The use of bovine lactoferrin is considered a promising option in treating oropharyngeal candidiasis. Here we review the results of in vitro and in vivo studies that have examined the antimicrobial characteristics of bovine lactoferrin as an adjunctive therapy for oropharyngeal candidiasis.